Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults
The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.
Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds
Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...